- GHINEA, Narcyz et al. Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. The Lancet, 2016. http://dx.doi.org/10.1016/S0140-6736(16)32051-7.
- HUSSAARTS, Leonie et al. Product development programs for neglected tropical diseases: A crucial role for expert meetings. PLOS Neglected Tropical Diseases, v. 11, n. 2, p. e0005183, 2017. http://dx.doi.org/10.1371/journal.pntd.0005183.
- DE CAMPOS, Thana Cristina. The Global Health Crisis: Ethical Responsibilities. Cambridge University Press, 2017. http://bit.ly/2mzUnN6.
- ENDRENYI, Laszlo; DECLERCK, Paul Jules; CHOW, Shein-Chung (Ed.). Biosimilar Drug Product Development. 2017. http://dx.doi.org/10.1201/9781315119878.
- PETER, J. ‘Science Tikkun’: Repairing the World through the Science of Neglected Diseases, Science Diplomacy, and Public Engagement. 2017. http://hdl.handle.net/1969.1/158838.
We urgently need new drugs, diagnostics, and vaccines for these new Anthropocene-driven diseases. Our recent finding that these infections now mostly strike people who live in poverty in large and wealthier G20 economies – a concept known as ‘blue marble health’ – indicates that the problem is not necessarily the lack of financial resources, but instead the inability to mobilize those resources appropriately. Under the auspices of a new Science Tikkun framework there is opportunity to create a new movement linking research and development (R&D) with public engagement in order to advocate for this essential support and create new products in a modern geopolitical context.
- LE DUC, James W.; NATHANSON, Neal. Emerging Viral Diseases. 2016. http://dx.doi.org/10.1016/B978-0-12-800964-2.00016-1 (mirror).
- FELDMAN, Robin; WANG, Connie. A Citizen’s Pathway Gone Astray—Delaying Competition from Generic Drugs. New England Journal of Medicine, 2017. http://doi.org/10.1056/NEJMp1700202.
A recent large-scale study we conducted using 12 years of FDA data reveals that the concerned citizen is frequently a drug company raising frivolous or questionable claims in a last-ditch effort to hold off competition.
- SCOPEL, Carolinne Thays. Modelo de análise das parcerias para o desenvolvimento produtivo de medicamentos na perspectiva da saúde pública. 2016. http://pesquisa.bvsalud.org/bvsvs/resource/es/ens-34988.
- TAVANI, Daniele et al. Growth, Income Distribution, and the ‘Entrepreneurial State’. 2017. http://bit.ly/2nQ345K.
- SELLONI, Daniela. New Forms of Welfare: Relational Welfare, Second Welfare, Co-production. In: CoDesign for Public-Interest Services. Springer International Publishing, 2017. p. 27-36. http://bit.ly/2nQ5bGT.
- MOORE, Michael J.; SNYDER, Edward A.; HUGHES, James W. Napsterizing Pharmaceuticals: Access, Innovation, and Welfare. 2011. http://bit.ly/2nQdUsn.
- JAIN, Vageesh; ALAM, Azeem. Redefining universal health coverage in the age of global health security. BMJ Global Health, v. 2, n. 2, p. e000255, 2017. http://doi.org/10.1136/bmjgh-2016-000255.
- MC CONALOGUE, David et al. International consultation on long-term global health research priorities, research capacity and research uptake in developing countries. Health Research Policy and Systems, v. 15, n. 1, p. 24, 2017. http://doi.org/10.1186/s12961-017-0181-0.